Breaking News

Alkermes Unveils New Drug Candidates

Outlines portfolio pipeline progress

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes will present an overview of its pipeline at an R&D Day meeting for analysts and investors, highlighting three new drug candidates: a monomethyl fumarate (MMF) prodrug for the treatment of multiple sclerosis; ALKS 7106 for the treatment of pain; and RDB 1419, a cancer immunotherapy candidate based on interleukin-2 (IL-2) and its receptors, the company’s first proprietary biologic.   In addition, the company will provide details on later-stage pipeline candidates including: commercial...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters